Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency
Methods of making the M or L complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), and methods of using to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex.
1. A method for the isolation of an L complex or a M complex of a botulinum neurotoxin type E, comprising the steps of:
a) passing a solution comprising an L complex or an M complex of a botulinum neurotoxin type E through a functionalized ion exchange column comprising 2-(diethylamino)ethyl or acetate (O—CH 2 COO); and
b) recovering the product;
wherein the M-complex comprises: a neurotoxin binding protein (NBP) bound to a Clostridium type E botulinum neurotoxin (BoNT/E), said M-complex with a molecular weight of about 250 kDa to about 300 kDa; and
wherein the L-complex comprises: the neurotoxin binding protein (NBP) bound to the Clostridium type E botulinum neurotoxin (BoNT/E), and a neurotoxin associated protein of 80, 60, 40, and 18 kDa (NAP-80; NAP-60, NAP-40, and NAP-18).
2. The method of claim 1 , wherein the L complex is isolated using the functionalized ion exchange column comprising beads having a size of 40 μm to 125 μm.
3. The method of claim 1 , wherein the M complex is isolated using the functionalized ion exchange column comprising beads having a size of 40 μm to 125 μm.
4. The method of claim 1 , wherein the solution comprising the M complex and/or comprising the L complex of the botulinum neurotoxin E and NBP of step (a) is obtained comprising the steps of:
a) providing a cultured bacteria grown in a media producing the L complex or the M complex of the botulinum neurotoxin E and a neurotoxin binding protein (NBP) and other non-toxin proteins comprising one or more neurotoxin associated proteins (NAPs) that are coded and expressed as part of a cluster of genes of the botulinum neurotoxin E;
b) centrifuging and pelletizing the cultured bacteria grown in the media of step (a);
c) stirring the solution of the pelletized culture at 0° C. to 10° C. over a period of 4 to 24 hours;
d) centrifuging the stirred solution of step (c) to obtain a supernatant;
e) precipitating and filtering the supernatant to obtain a precipitate; and
f) dissolving the precipitate obtained in step (e), centrifuging and filtering to obtain a solution comprising the M complex and/or the L complex of the botulinum neurotoxin E using a column chromatography comprising the functionalized ion exchange column.
5. The method of claim 4 , wherein a pH of step (c) through step (f) is maintained in the range of 4.5 to 7.5.
6. The method of claim 4 , wherein the step (c) further comprises stirring the solution in a sodium phosphate buffer at a pH in the range of 5 to 7.
7. The method of claim 4 , wherein the step (f) further comprises stirring the solution in a sodium citrate buffer at a pH in the range of 5 to 7.
8. The method of claim 1 , further comprising administering the M complex and/or the L complex of the botulinum neurotoxin E and NBP to treat wrinkles, glabellar lines, and cervical dystonia.
9. The method of claim 1 , further comprising administering the M complex or the L complex of the botulinum neurotoxin E and NBP to treat one or more of: acute pain, neuromuscular disorder, muscle spasm, excessive sweating,, and itching.
10. The method of claim 1 , further comprising administering the M complex or the L complex of the botulinum neurotoxin E and NBP through intramuscular (IM), intraperitoneal (IP), subcutaneous (SC), or topical routes.